Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Frexalimab from the Phase 2 Open-label Extension in Participants with Relapsing Multiple Sclerosis: 2-year Results

Author:Vermersch, Patrick   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Krieger, Stephen   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giov,   

Session Name:S3: Multiple Sclerosis: Clinical Trials  

Topic:Multiple Sclerosis  

Program Number:S3.006  

Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France , Lille, France  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Biostatistics, UAB School of Public Health, Birmingham, AL, USA, Birmingham, AL  Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine  Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria  First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic  Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain  Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY  Sanofi, Gentilly, France, Gentilly, France  Sanofi, Bridgewater, NJ, USA, Bridgewater, NJ  Sanofi, Cambridge, MA, USA, Cambridge, MA  Queen Mary University of London, London, United Kingdom , London, United Kingdom  

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes During 5–7 Years of Ozanimod in Relapsing MS: Final Results from the DAYBREAK Open-label Extension Study

Author:Cohen, Jeffrey A.   Arnold, Douglas L.   DeLuca, John   Hartung, Hans-Peter   Kappos, Ludwig   Comi, Giancarlo   Selmaj, Krzysztof W.   Steinman, Lawrence   Bar-Or, Amit   Montalban, Xavier   Havrdová, Eva K.   Sheffield, James K.   Pachai, Chahin   Cheng, Chun-Yen   Riolo, Jon V.   C,   

Session Name:P3: Multiple Sclerosis: Imaging of Demyelinating and Neuroinflammatory Diseases  

Topic:Multiple Sclerosis  

Program Number:P3.005  

Author Institution:Kessler Foundation, West Orange, New Jersey, and Department of Physical Medicine & Rehabilitation and Neurology & Neurosciences, Rutgers - New Jersey Medical School, Newark, New Jersey, USA, West Orange, NJ  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Department of Neurology, Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Vita-Salute San Raffaele University, and Casa di Cura Igea, Milan, Italy, Milan, Italy  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, USA, Stanford, CA  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, Philadelphia, PA  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Bristol Myers Squibb, Princeton, New Jersey, USA, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey, USA, Bedminster, NJ  

Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis